Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey
NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey
A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:
• Decisions in treatment and tests through disease stages
• Factors influencing their decisions
• Barriers to optimal care
• Confidence in treatment.
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
• Design messages to advance brand performance
Table of Contents
Executive Summary5
Chapter 1: Introduction7
Table 1: Treatment Options in Advanced Lung Cancer7
Chapter 2: Respondent Demographics9
Table 2: Eligibility Criteria for Survey Participation9
Figure 2.1 Gender of Survey Respondents9
Figure 2.2 Years since Medical School Graduation10
Figure 2.3 Practice Settings10
Figure 2.4 Practices in NCI Cancer Centers11
Figure 2.5 Geographic Settings11
Figure 2.6 Survey Respondents by State's Lung Cancer Mortality12
Figure 2.7 Number of Physicians in Practice Groups13
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13
Chapter 3: Treatment of a Smoker with Squamous Cell Carcinoma14
Figure 3.1 Laboratory studies to be done on the tumor tissue14
Figure 3.2 First line chemotherapy regimen15
Figure 3.3 Factors Influencing Treatment Decisions16
Figure 3.4 Confidence in treating this patient to an optimal outcome18
Figure 3.5 Next step in management19
Figure 3.6 Subsequent treatment regimen21
Figure 3.7 Treatment at next cancer progression22
Figure 3.8 Factors influencing treatment decisions23
Figure 3.9 Barriers to management of advanced lung cancer25
Chapter 4: Summary27
Appendix A: Survey Instrument29
Companies mentioned
Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article